Bortezomib induces long-term remission in children with immune thrombotic thrombocytopenic purpura, refractory to plasma exchange, glucocorticoids, and rituximab: A report on two cases

Pediatr Blood Cancer. 2021 Apr;68(4):e28818. doi: 10.1002/pbc.28818. Epub 2020 Nov 19.

Authors

Alexey Maschan¹, Uliana Petrova¹, Irina Kalinina¹, Elena Kurnikova¹, Daria Fedorova¹, Dina Baidildina¹, Natalia Kotskaya¹, Pavel Avdonin², Galina Novichkova¹

Affiliations

¹ Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
² Koltsov Institute of Developmental Biology RAS, Moscow, Russia.

PMID: 33211391
DOI: 10.1002/pbc.28818

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Bortezomib / therapeutic use*
Child
Child, Preschool
Female
Glucocorticoids / therapeutic use*
Humans
Plasma Exchange*
Purpura, Thrombocytopenic, Idiopathic / drug therapy
Purpura, Thrombocytopenic, Idiopathic / therapy*
Rituximab / therapeutic use*

Substances

Antineoplastic Agents
Glucocorticoids
Rituximab
Bortezomib